News Releases

Month Year

Email Alerts

Feb 12, 2009

Insmed Sells Follow-on Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million
Jan 21, 2009

Insmed and Premacure Announce European Orphan Designation for IPLEX(TM) in Retinopathy of Prematurity in Infants
Dec 26, 2008

Insmed to Appeal Delisting Notification From Nasdaq
Dec 23, 2008

Insmed Announces that NASDAQ Extends Temporary Suspension of Minimum Bid Closing Price Rule
Nov 25, 2008

Insmed to Present at Sanford C. Bernstein Biosimilars Long View Conference
Nov 18, 2008

Insmed to Participate in Federal Trade Commission Roundtable on Follow-on Biologic Drugs: Framework for Competition and Continued Innovation
Nov 10, 2008

Insmed Gains Royalty-Free Worldwide Rights for IPLEX(TM) in Connection with Potential Expanded Access ALS Programs
Nov 5, 2008

Insmed to Present at Upcoming Healthcare Conferences
Oct 30, 2008

Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008

Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008
- Photos 4
Oct 22, 2008

NASDAQ's Temporary Suspension of Minimum Bid Closing Price Rules Extends Insmed's Compliance Date to March 20, 2009
Oct 21, 2008

Insmed Announces That NASDAQ Temporarily Suspends Minimum Bid Closing Price Rule
Oct 20, 2008

Insmed to Host Third Quarter 2008 Conference Call
Oct 14, 2008

Insmed Initiates Clinical Study for Follow-on Biologic Version of Neulasta(R)
Oct 14, 2008

Insmed to Seek Shareholder Approval for Reverse Split
Sep 23, 2008

Insmed and Premacure Cite Study Results Demonstrating Potential Effectiveness of IPLEX(TM) in Preventing Blindness in Premature Infants
Sep 15, 2008

Insmed to Present at Biosimilars 2008 Conference
Sep 4, 2008

Insmed to Present at BioPharm Asia 2008 Conference
Sep 3, 2008

NASDAQ Hearing Panel Grants Insmed Request for Continued Listing on the NASDAQ Stock Market
Aug 8, 2008

Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
Jul 28, 2008

Jim Miller, Ph.D. Joins Insmed Therapeutic Proteins as Vice President of Process Development
Jul 25, 2008

Insmed to Host Second Quarter 2008 Conference Call
Jul 25, 2008

Insmed CEO to Present at Drug Discovery & Development Conference
Jul 22, 2008

Insmed CEO to Present at Congressional Briefing on Follow-On Biologics
Jul 21, 2008

Insmed Provides Update on IPLEX(TM) Programs
Jul 17, 2008

Insmed Partners With Bill Thomas, Former House Ways and Means Chairman, as Strategic Advisor
Jul 14, 2008

Insmed Retains RBC Capital Markets as Strategic Financial Advisor
Jul 10, 2008

Insmed Announces First Human Bioequivalence Data for a Follow-on Biologic by a U.S. Company
Jul 9, 2008

Insmed to Present at Collins Stewart Fourth Annual Growth Conference
Jun 20, 2008

Insmed to Request Hearing Before NASDAQ Panel to Review NASDAQ Staff Determination
May 8, 2008

Insmed Announces First Quarter 2008 Financial Results
May 8, 2008

/C O R R E C T I O N -- Insmed Inc./
Apr 29, 2008

Insmed Provides Update on Follow-On Biologics and IPLEX(TM) Programs
Apr 24, 2008

Insmed to Host First Quarter 2008 Conference Call
Apr 22, 2008

Insmed to Present at CBI Follow-On Biologics Conference
Apr 16, 2008

Insmed Initiates Clinical Study for Follow-on Biologic Version of Neupogen(R)
Apr 10, 2008

Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
Mar 8, 2008

Insmed Announces Additional Information in Compliance With NASDAQ Rules
Mar 4, 2008

Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results
Feb 28, 2008

Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
Feb 19, 2008

Insmed to Host Fourth Quarter and Full-Year 2007 Conference Call
Feb 11, 2008

Study by Leading Economist Identifies Potential for $378 Billion of Savings From Follow On Biologics
Feb 5, 2008

Insmed Launches National Awareness Campaign Surrounding Follow-On Biologics
Feb 5, 2008

Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
Jan 28, 2008

Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
Jan 22, 2008

Insmed Completes External Assessment of Myotonic Muscular Dystrophy Market
Dec 18, 2007

Insmed Receives FDA Orphan Drug Designation for IPLEX(TM) in the Treatment of Myotonic Muscular Dystrophy
Dec 12, 2007

Insmed Awarded $2.1 Million by Muscular Dystrophy Association
Dec 6, 2007

Insmed to Present at the IBC 5th Annual Global Follow-On Biologics Conference
Dec 6, 2007

Insmed Appoints Dennis M. Lanfear to Board Of Directors
Dec 3, 2007

Insmed Retains FD and Gibraltar Associates for Investor Relations and Corporate Communications

Show per page

Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your
email alerts.

View the latest Insmed Investor Presentation

Download

Our Global Company

Current Clinical Trials

Our Research Team

Our Global Company

Current Clinical Trials

Our Research Team

Footer